ProCE Banner Activity

KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer

Slideset Download
Conference Coverage
Median overall survival was 11 months, with a median duration of response of 40 weeks with pembrolizumab in PD-L1–positive gastric cancer.

Released: June 02, 2015

Expiration: May 31, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation